Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. It is also developing ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-440-9333
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$250,000.00
Profitability
Miscellaneous
Employees49
OptionableOptionable
Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions
What is Intra-Cellular Therapies' stock symbol?
Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."
How were Intra-Cellular Therapies' earnings last quarter?
Intra-Cellular Therapies Inc (NASDAQ:ITCI) issued its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.09. View Intra-Cellular Therapies' Earnings History.
When is Intra-Cellular Therapies' next earnings date?
What price target have analysts set for ITCI?
7 analysts have issued 12-month price objectives for Intra-Cellular Therapies' stock. Their forecasts range from $25.00 to $37.00. On average, they anticipate Intra-Cellular Therapies' share price to reach $29.7143 in the next year. This suggests a possible upside of 136.8% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.
What is the consensus analysts' recommendation for Intra-Cellular Therapies?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.
What are Wall Street analysts saying about Intra-Cellular Therapies stock?
Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:
- 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (1/10/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and price target of $32. On Wednesday, BMO Intra-Cellular reported 3Q18 financial performance ending the period with cash of $376M. Our model projects sufficient funding through several clinical milestones including NDA acceptance/approval of lumateperone for schizophrenia and P3 data in bipolar depression (two trials, now expected in 1H19). The key questions on the earnings call, which we view as resulting in a market inefficiency, centered on the data analysis and release of the P3 401 & 404 studies of luma’ in BpD. First, we don’t expect the efficacy data for the two studies to be pooled; but analyzed separately at the same time." (11/7/2018)
Has Intra-Cellular Therapies been receiving favorable news coverage?
News articles about ITCI stock have been trending extremely positive on Saturday, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intra-Cellular Therapies earned a news sentiment score of 4.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the next few days.
Who are some of Intra-Cellular Therapies' key competitors?
Some companies that are related to Intra-Cellular Therapies include Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Endo International (ENDP), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), Mirati Therapeutics (MRTX), Opko Health (OPK), Ironwood Pharmaceuticals (IRWD), Endocyte (ECYT) and Innoviva (INVA).
Who are Intra-Cellular Therapies' key executives?
Intra-Cellular Therapies' management team includes the folowing people:
- Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 66)
- Mr. Lawrence J. Hineline CPA, VP of Fin., CFO, Treasurer & Assistant Sec. (Age 63)
- Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 68)
- Mr. Michael I. Halstead J.D., Sr. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 46)
- Dr. Andrew Satlin M.D., Exec. VP & Chief Medical Officer (Age 64)
Who are Intra-Cellular Therapies' major shareholders?
Intra-Cellular Therapies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include First Midwest Bank Trust Division (0.60%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.
Which major investors are buying Intra-Cellular Therapies stock?
ITCI stock was acquired by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi. View Insider Buying and Selling for Intra-Cellular Therapies.
How do I buy shares of Intra-Cellular Therapies?
Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intra-Cellular Therapies' stock price today?
One share of ITCI stock can currently be purchased for approximately $12.55.
How big of a company is Intra-Cellular Therapies?
Intra-Cellular Therapies has a market capitalization of $690.10 million and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-97,770,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Intra-Cellular Therapies employs 49 workers across the globe.
What is Intra-Cellular Therapies' official website?
How can I contact Intra-Cellular Therapies?
Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]
MarketBeat Community Rating for Intra-Cellular Therapies (NASDAQ ITCI)
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe ITCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
